Jardiance Geriatric (65+ ) Dosing: What Clinicians and Patients Need to Know

Does Age Alone Change the Empagliflozin Dose?

No. The FDA-approved prescribing information for Jardiance does not list age as an independent reason to modify the dose. Pharmacokinetic studies show that age, by itself, has only a minor effect on empagliflozin exposure, an approximately 14% increase in AUC in subjects older than 65 compared with younger adults, a difference the FDA judged clinically insignificant. Renal function, not age, is the variable that matters.

Why Renal Function Matters More Than Birthdate

Empagliflozin works by blocking sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule, so its glucose-lowering effect depends directly on glomerular filtration. As eGFR falls, less glucose is filtered, and the drug delivers progressively less glycemic benefit. For older adults, who lose roughly 0.5 to 1 mL/min/1.73 m² of eGFR per year after age 40, this means annual eGFR checks are not optional, they are the primary gating mechanism for continued use. Data from the National Kidney Foundation confirm that adults aged 70 and older carry a disproportionate burden of CKD stage 3 or worse.

The Three Indication-Specific eGFR Thresholds

| Indication | Minimum eGFR to Initiate | Dose to Use | |---|---|---| | Type 2 diabetes (glycemic control) | ≥ 30 mL/min/1.73 m² | 10 mg, may increase to 25 mg | | Heart failure (HFrEF / HFpEF) | ≥ 20 mL/min/1.73 m² | 10 mg once daily | | Chronic kidney disease | ≥ 20 mL/min/1.73 m² | 10 mg once daily |

For heart failure and CKD indications, the glycemic-efficacy argument disappears; the cardio-renal protection mechanism is only partially dependent on filtration, which is why the threshold drops to eGFR 20. The FDA updated these thresholds in 2023 based on data from EMPEROR-Reduced, EMPEROR-Preserved, and EMPA-KIDNEY.

EMPA-REG OUTCOME: What the Trial Data Show for Older Patients

EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease across 42 countries. The primary finding, published in the New England Journal of Medicine in 2015, was a 38% relative reduction in cardiovascular death (hazard ratio 0.62; 95% CI 0.49 to 0.77; P<0.001) compared with placebo at a median follow-up of 3.1 years.

Age-Stratified Subgroup Findings

The trial included a substantial proportion of adults aged 65 and older, and pre-specified subgroup analyses showed that the cardiovascular mortality benefit was directionally consistent across age groups. Patients 65 and older in the empagliflozin arm also showed a 35% reduction in hospitalization for heart failure versus placebo, a finding that reinforced guideline adoption well before the dedicated heart failure trials were completed.

HbA1c and Glycemic Findings Relevant to Older Patients

In EMPA-REG OUTCOME, mean HbA1c reduction was approximately 0.54% with empagliflozin 10 mg versus 0.02% with placebo at week 206 [1]. For older patients with a less-stringent HbA1c target (7.5 to 8.0%, per American Diabetes Association Standards of Care 2024), this modest glycemic effect may be secondary to the cardiovascular and renal benefits.

The ADA 2024 guidelines state directly: "For older adults with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, SGLT2 inhibitors with proven cardiovascular benefit are preferred agents independent of HbA1c target." [2]

Starting, Titrating, and Monitoring Empagliflozin in Patients 65+

Starting Dose and Titration Schedule

Begin with 10 mg once daily taken in the morning, with or without food. After 4 to 8 weeks, if the patient tolerates the drug and eGFR remains at or above 45 mL/min/1.73 m², clinicians may increase to 25 mg once daily to achieve additional HbA1c reduction (approximately 0.2 to 0.3% incremental benefit, per FDA prescribing information). The 25 mg dose should not be used when eGFR falls below 45 because glycemic benefit is attenuated and volume-depletion risk rises without meaningful offsetting efficacy.

Baseline Labs Before Starting

Before prescribing in any patient 65 or older, obtain:

• Serum creatinine with calculated eGFR (CKD-EPI 2021 equation preferred)
• Urine albumin-to-creatinine ratio (UACR)
• Serum potassium (relevant if co-prescribed with ACE inhibitors or ARBs)
• Hemoglobin or hematocrit (SGLT2 inhibitors raise hematocrit 2 to 3 percentage points; a falsely elevated baseline can obscure later anemia)
• Blood pressure (sitting and standing to screen for orthostatic hypotension)

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 CKD guideline recommends UACR measurement alongside eGFR for every patient being evaluated for SGLT2 inhibitor initiation, because UACR reduction is an independent prognostic marker.

Ongoing Monitoring Intervals

| Parameter | Frequency | |---|---| | eGFR / serum creatinine | Every 6 months if stable; every 3 months if eGFR 20 to 45 | | Blood pressure (sitting and standing) | Every clinic visit | | Signs of genital mycotic infection | Every visit; patient-reported | | Serum potassium | Every 6 months if on RAAS blockade | | HbA1c | Every 3 months until at target, then every 6 months |

Volume Depletion and Hypotension: The Priority Safety Signal in Older Adults

Empagliflozin produces osmotic diuresis by excreting 60 to 80 grams of glucose per day in the urine, which draws approximately 300 to 400 mL of additional water daily. In young, healthy adults this is clinically trivial. In a 72-year-old taking furosemide 40 mg daily, an ACE inhibitor, and an ARB, the additive fluid loss can produce clinically significant orthostatic hypotension within days.

The Evidence on Orthostatic Hypotension

A 2019 pharmacoepidemiologic cohort study published in JAMA Internal Medicine found that SGLT2 inhibitor initiation was associated with a 1.8-fold increased odds of a hypotension-related emergency department visit in adults over 65 compared with DPP-4 inhibitor initiation (adjusted OR 1.84; 95% CI 1.18 to 2.88). Volume status assessment before starting, and at the first follow-up visit, is not a box-checking formality.

Practical Steps to Reduce Volume-Depletion Risk

1. Review the diuretic regimen. Consider reducing loop diuretic dose by 25 to 50% at empagliflozin initiation if the patient is already at or near dry weight.
2. Counsel patients to hold empagliflozin during acute illness, fever, or vomiting ("sick-day rules"), following the NHS Diabetes guidance on SGLT2 inhibitor sick-day management.
3. Measure standing blood pressure 2 weeks after initiation.
4. Set a hard stop: if systolic BP falls below 100 mmHg on standing, withhold the dose and reassess.

Falls and Fracture Risk in Older Patients on Empagliflozin

What the Data Show

Orthostatic hypotension and polypharmacy together are the leading modifiable contributors to falls in adults over 65. The CDC reports that falls are the leading cause of injury-related death in this population. Because empagliflozin can lower blood pressure and because older adults may already be on antihypertensives, a drug that modestly drops both volume and blood pressure deserves careful falls-risk screening.

EMPA-REG OUTCOME did not show a statistically significant increase in fracture rates with empagliflozin versus placebo (HR 0.96; 95% CI 0.75 to 1.22), which stands in contrast to canagliflozin data from CANVAS (fracture HR 1.26; 95% CI 1.04 to 1.52). The mechanistic difference may relate to canagliflozin's inhibition of SGLT1 in the gut, which affects phosphate absorption. Empagliflozin's fracture profile appears safer, but falls prevention remains a clinical priority regardless of fracture signal.

Falls Prevention Checklist for Clinicians

• Complete the CDC STEADI falls screening at every visit for patients 65 and older on empagliflozin.
• Review all medications causing sedation, orthostasis, or vestibular effects.
• Refer to physical therapy for balance training if the Timed Up and Go test exceeds 12 seconds.
• Advise adequate hydration (6 to 8 cups of water daily) to counteract osmotic diuresis without driving excessive urination at night, which increases fall risk during nocturnal trips to the bathroom.

Genital Mycotic Infections and UTI Risk in Older Women

Older women carry higher background rates of vulvovaginal candidiasis and urinary tract infections than younger women, partly because of estrogen-deficient tissue atrophy and partly because of impaired immune function. Glucosuria created by empagliflozin feeds Candida in the perineal environment.

In pooled analysis of empagliflozin phase III trials, genital mycotic infections occurred in 6.4% of women on empagliflozin versus 1.8% on placebo, roughly a 3.5-fold increase. Rates in postmenopausal women without local estrogen therapy may be higher.

Clinicians should ask directly about genital symptoms at each visit, because older women frequently do not volunteer this complaint. Local vaginal estrogen (e.g., estradiol 10 mcg vaginal insert twice weekly) reduces vulvovaginal atrophy and may reduce infection susceptibility; the Menopause Society 2023 position statement supports its safety in most postmenopausal women, including those with a history of breast cancer when systemic hormones are contraindicated.

Drug-Drug Interactions Relevant to Older Adults

Polypharmacy is ubiquitous in patients aged 65 and older. The average Medicare beneficiary takes 4.5 chronic medications. Empagliflozin carries a low intrinsic drug-drug interaction burden, it is not a CYP450 substrate, but several pharmacodynamic interactions demand attention.

Diuretics

Co-administration with loop diuretics (furosemide, torsemide) or thiazides amplifies the osmotic diuresis. Sodium depletion is additive. When adding empagliflozin to a patient on furosemide 40 mg or higher, consider dose reduction of the loop diuretic and recheck electrolytes at 2 weeks. FDA labeling explicitly flags this interaction.

Insulin and Sulfonylureas

Empagliflozin does not cause hypoglycemia on its own, but it lowers glucose enough to tip a patient into hypoglycemia when combined with insulin or sulfonylureas. In the ADA/EASD 2022 consensus report on T2D management, sulfonylurea dose reduction by 25 to 50% is recommended at SGLT2 inhibitor initiation if the patient's HbA1c is near target. For older adults, reducing insulin by 10 to 20% is a reasonable starting precaution.

NSAIDs

Non-steroidal anti-inflammatory drugs reduce renal prostaglandin synthesis and can acutely drop eGFR. Combined with empagliflozin's volume effects, short courses of NSAIDs can precipitate acute kidney injury in older patients with borderline renal function. Clinicians should counsel patients explicitly to avoid over-the-counter ibuprofen and naproxen while on empagliflozin, and to use acetaminophen instead for mild pain. The American Geriatrics Society Beers Criteria 2023 already lists NSAIDs as potentially inappropriate in most older adults, independent of SGLT2 inhibitor use.

Diabetic Ketoacidosis Risk: Atypical Presentation in Older Patients

Euglycemic diabetic ketoacidosis (DKA) is a rare but life-threatening adverse effect of SGLT2 inhibitors, occurring in roughly 0.1 to 0.2% of users per year based on FDA postmarketing surveillance data. In older patients, the presentation may be atypical, blood glucose can be below 250 mg/dL, nausea and lethargy may be attributed to other causes, and ketones may not be checked unless the clinician suspects the diagnosis.

Risk is highest with:

• Very low carbohydrate diets (common in motivated older patients)
• Surgical procedures or prolonged fasting
• Acute illness or infection
• Type 1 diabetes misclassified as type 2

Hold empagliflozin at least 3 days before elective surgery. Resume only after the patient is eating normally and eGFR has been rechecked, per Endocrine Society clinical practice guidance.

Deprescribing Empagliflozin in Older Adults: When to Stop

Deprescribing SGLT2 inhibitors is underaddressed in most clinical guidelines. For older adults, the calculus shifts as renal function declines, frailty progresses, or life expectancy shortens. The following framework, developed from KDIGO 2022, ADA 2024, and AGS Beers 2023 recommendations, provides explicit stopping triggers.

Clinical Triggers to Discontinue Empagliflozin

Stop immediately:

• eGFR falls below 20 mL/min/1.73 m² on two consecutive readings (or below 30 for T2D glycemic-only indication)
• Recurrent AKI episodes (two or more episodes in 12 months)
• Hospitalization for euglycemic DKA
• Recurrent urinary tract infections requiring antibiotics (three or more per year) with no other correctable cause

Consider stopping or holding:

• Patient entering hospice or comfort-focused care (glycemic control no longer a treatment goal)
• Severe frailty with Clinical Frailty Scale score of 7 or higher, where any fall risk reduction outweighs cardiovascular benefit
• Persistent symptomatic orthostatic hypotension despite diuretic reduction
• Patient initiates a ketogenic or very-low-carbohydrate diet without medical supervision

Do not stop based on age alone. A well-monitored 82-year-old with eGFR 45 and established heart failure may derive meaningful mortality benefit from empagliflozin for years to come, consistent with the EMPEROR-Reduced population where 25% of participants were older than 70. See EMPEROR-Reduced (N=3,730) for subgroup data.

How to Stop Safely

Empagliflozin does not require tapering. Stopping abruptly is safe, there is no rebound hyperglycemia beyond return to pre-treatment baseline and no withdrawal syndrome. Clinicians should recheck HbA1c 8 to 12 weeks after stopping to determine whether another agent is needed to fill the glycemic gap. Blood pressure may rise modestly after discontinuation, as the osmotic-diuretic antihypertensive effect resolves within 2 to 3 weeks.

Renal Dosing Summary Table

| eGFR (mL/min/1.73 m²) | T2D Glycemic Use | Heart Failure Use | CKD Use | |---|---|---|---| | ≥ 45 | 10 mg or 25 mg daily | 10 mg daily | 10 mg daily | | 30 to <45 | 10 mg daily only | 10 mg daily | 10 mg daily | | 20 to <30 | Not recommended | 10 mg daily | 10 mg daily | | <20 | Contraindicated | Contraindicated | Contraindicated | | Dialysis | Contraindicated | Contraindicated | Contraindicated |

Source: FDA Jardiance prescribing information, 2023; EMPA-KIDNEY (NEJM 2023).

Special Populations Within the Geriatric Age Group

Adults 75 and Older

Patients over 75 were underrepresented in the major empagliflozin trials. EMPA-REG OUTCOME enrolled patients up to age 82, but fewer than 10% of the trial population was 75 or older. Extrapolation requires clinical judgment. For this age group, the priority is renal monitoring every 3 months (rather than 6), a lower threshold for diuretic reduction, and a proactive conversation about goals of care if frailty is progressing.

Patients With Cognitive Impairment

Empagliflozin's urinary glucose excretion increases urinary frequency, which can worsen urgency incontinence in patients with cognitive impairment or limited mobility. Caregivers should be briefed. If nocturia leads to two or more nighttime voids and the patient has documented fall risk, the benefit-risk calculation should be revisited. The American Geriatrics Society lists urinary urgency as a falls-precipitating factor in older adults.

Patients on Concurrent Dapagliflozin or Canagliflozin

Combination SGLT2 inhibitor therapy has no proven benefit and doubles the risk of urinary infections and volume depletion. Do not co-prescribe two SGLT2 inhibitors. If switching agents, a 24- to 48-hour washout period is sufficient given empagliflozin's half-life of approximately 12 hours, per published pharmacokinetic data.